A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study
Matthew K Hoffman,Shivaprasad S Goudar,Bhalachandra S Kodkany,Norman Goco,Marion Koso-Thomas,Menachem Miodovnik,Elizabeth M McClure,Dennis D Wallace,Jennifer J Hemingway-Foday,Antoinette Tshefu,Adrien Lokangaka,Carl L Bose,Elwyn Chomba,Musaku Mwenechanya,Waldemar A Carlo,Ana Garces,Nancy F Krebs,K Michael Hambidge,Sarah Saleem,Robert L Goldenberg,Archana Patel,Patricia L Hibberd,Fabian Esamai,Edward A Liechty,Robert Silver,Richard J Derman
DOI: https://doi.org/10.1186/s12884-017-1312-x
2017-05-03
Abstract:Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long term disability throughout the world. Though complex in its origins, a growing body of evidence suggests that first trimester administration of low dose aspirin (LDA) may substantially reduce the rate of PTB. Methods: Hypothesis: LDA initiated in the first trimester reduces the risk of preterm birth. Study Design Type: Prospective randomized, placebo-controlled, double-blinded multi-national clinical trial conducted in seven low and middle income countries. Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin. Intervention: Daily administration of low dose (81 mg) aspirin, initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA, compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly. Outcomes: Primary outcome: Incidence of PTB (birth prior to 37 0/7 weeks GA). Secondary outcomes Incidence of preeclampsia/eclampsia, small for gestational age and perinatal mortality. Discussion: This study is unique as it will examine the impact of LDA early in pregnancy in low-middle income countries with preterm birth as a primary outcome. The importance of developing low-cost, high impact interventions in low-middle income countries is magnified as they are often unable to bear the financial costs of treating illness. Trial registration: ClinicalTrials.gov identifier: NCT02409680 Date: March 30, 2015.